|
|
Håkan Åström, Med. Dr. h.c.
Chairman
Dr. Åström is a board member of Biovitrum (Chairman), Karolinska Institutet (Vice Chairman), Biolipox AB (Chairman), Ferrosan AS (Chairman), Orexo AB (Chairman), SANOS AS (Chairman), and Topotarget AS (Chairman). Dr. Åström was formerly CEO of Kabi Pharmacia and Senior Vice President of Pharmacia Corporation.
|
|
|
Mathias Uhlén, Ph.D.
Deputy Chairman
Prof. Uhlén is a co-founder of Affibody AB, and Professor of Biotechnology at the Royal Institute of Technology in Stockholm. He is a Program Director of the Swedish Human Protein (HPA) program, funded by the Knut and Alice Wallenberg foundation, and a Board member of Atlas Antibodies AB, Biotage AB, KTH Holding AB, Nordiag AS, Novozymes AS, Skanditek AB and SweTree Technologies AB. Prof. Uhlén was appointed to Affibody’s Board of Directors in 1998. |
|
|
Björn Odlander, M.D., Ph.D.
Director
Dr. Odlander is President of Odlander, Fredrikson & Co., and founding partner of HealthCap. He joined Affibody's Board of Directors in 2000 and currently serves on the Boards of Bonesupport AB, Cardoz AB and LTB4 AB. |
|
|
Karl Swartling
Director
Karl Swartling is Managing Director and Co-Head of Investor Growth Capital Europe (Stockholm). Karl also serves on the Board of NeuroNova AB and is deputy board member in Atlas Antibodies AB, Tobii Technologies AB and Cambio Healthcare Systems AB. Karl spent 15 years with the McKinsey & Company consulting firm with main focus on Life Science. Karl Swartling holds an MBA from the Stockholm School of Economics. |
 |
Daniel Rosik
Employee Representative
|